Literature DB >> 23570878

Association of eNOS gene intron 4 a/b VNTR polymorphisms in children with nephrotic syndrome.

Hasan Dursun1, Aytul Noyan, Selcuk Matyar, Mithat Buyukcelik, Mustafa Soran, Nurcan Cengiz, Aysun K Bayazit, Gulsah Seydaoglu, Gulen Attila, Ali Anarat.   

Abstract

To investigate the association of endothelial nitric oxide synthase gene intron 4 (eNOS4) polymorphisms with nephrotic syndrome, the eNOS4 genotypes were assessed in 161 children with nephrotic syndrome in comparison with 78 healthy subjects. We classified the children with nephritic syndrome into 2 groups: as steroid-sensitive nephrotic syndrome (SSNS) (n=125) and steroid-resistant nephrotic syndrome (SRNS) (n=36). The eNOS4 polymorphisms were analyzed by polymerase chain reaction. The frequencies of eNOS4 aa, ab and bb genotypes were 3%, 31%, and 66% in all the nephrotic syndrome groups, and 1%, 23%, and 76% in the control group (x(2)=2.87, p>0.05). In addition, the frequencies of eNOS4 aa, ab and bb genotypes were 2%, 33%, and 65% in SSNS group, and 5%, 28%, and 67% in the SRNS group (x(2)=1.13, p=0.567). The present study is the first to investigate eNOS4 gene polymorphisms in children with SSNS and SRNS. Our data show that the eNOS4 gene polymorphisms were not associated with the development, frequent relapse and response to steroid in nephritic syndrome.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23570878     DOI: 10.1016/j.gene.2013.03.080

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  2 in total

1.  Genetic studies of nephrotic syndrome in Egyptian children.

Authors:  Rehab Elmougy
Journal:  J Appl Biomed       Date:  2021-10-12       Impact factor: 1.797

2.  The Endothelial Nitric Oxide Synthase Gene T-786C Polymorphism Increases Myocardial Infarction Risk: A Meta-Analysis.

Authors:  Xiang-Zhen Kong; Zheng-Yi Zhang; Lian-Hua Wei; Rui Li; Jing Yu
Journal:  Med Sci Monit       Date:  2017-02-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.